← Leaderboards
Gen Sheng Wu
Wayne State University
$3,435,264
Attributed
$3,435,264
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $507.8K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,435,264 · 4
By mechanism
R01$2,685,902 · 2
R21$749,362 · 2
Top collaborators
No co-investigators on record.
Most similar at Wayne State University
Same institution · by research overlap
- Ahmad R Heydari$1,229,952
- Kaladhar B. Reddy$2,718,148
- Cornelis Johan Elferink$17,242,434
- Wei-Zen Wei$6,644,720
- Lawrence E Flaherty$13,598,763
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMediatingPharmaceutical PreparationsCellsApoptosisSignal TransductionRegulationMalignant NeoplasmsComplexPhosphoric Monoester HydrolasesOverexpressionPublic Health RelevanceRelapsePlayMemberIn VivoCancer TherapyGrowthCessation Of LifeInhibitor/AntagonistDrug ResistanceClinical TrialsEffective TherapyIn Vitro
Grant awards (15)
Targeting Atg5 in platinum-resistant ovarian cancer$211,665
R21 · FY2022 · CA · contact PI
Targeting Atg5 in platinum-resistant ovarian cancer$179,988
R21 · FY2021 · CA · contact PI
Developing targeted therapies for triple-negative breast cancer$161,417
R01 · FY2020 · CA · contact PI
Developing targeted therapies for triple-negative breast cancer$315,400
R01 · FY2018 · CA · contact PI
Developing targeted therapies for triple-negative breast cancer$315,400
R01 · FY2016 · CA · contact PI
Developing targeted therapies for triple-negative breast cancer$315,400
R01 · FY2015 · CA · contact PI
Developing targeted therapies for triple-negative breast cancer$315,400
R01 · FY2014 · CA · contact PI
A novel role for PARP1 in regulation of autophagy$192,409
R21 · FY2014 · CA · contact PI
A novel role for PARP1 in regulation of autophagy$165,300
R21 · FY2013 · CA · contact PI
The Role of Phosphatase CL100/MKP1 in Human Cancer$59,282
R01 · FY2009 · CA · contact PI
The Role of Phosphatase CL100/MKP1 in Human Cancer$234,807
R01 · FY2008 · CA · contact PI
The Role of Phosphatase CL100/MKP1 in Human Cancer$234,807
R01 · FY2007 · CA · contact PI
The Role of Phosphatase CL100/MKP1 in Human Cancer$241,820
R01 · FY2006 · CA · contact PI
The Role of Phosphatase CL100/MKP1 in Human Cancer$247,640
R01 · FY2005 · CA
The Role of Phosphatase CL100/MKP1 in Human Cancer$244,529
R01 · FY2004 · CA